131-I-Metaiodobenzylguanidine Treatment of Malignant Phe

嗜铬细胞瘤是合成和分泌儿茶酚胺的嗜铬细胞的肿瘤。本项目检测131i -甲氧十二苄基胍（131I-MIBG）放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是检测前使用特异性药物（所谓的敏感剂）是否能提高131I-MIBG治疗在减少肿瘤大小、数量和肿瘤负担方面的疗效。中心假设是，在恶性嗜铬细胞瘤患者中，使用131I-MIBG治疗可破坏肿瘤细胞，从而减少肿瘤的大小和数量，减轻肿瘤负担；“增敏”程序增强了131I-MIBG的有效性。目前，这项新方案需要一些澄清，以完成与密歇根大学的合同，以便能够获得131-I-MIBG进行治疗，因此，到目前为止还没有患者入组研究。

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. Currently this new protocol needs some clarifications to complete the contract with the University of Michigan to be able to obtain 131-I-MIBG for treatment, therefore, no patients have been enrolled into the study so far.